Agenda
WEDNESDAY, OCTOBER 29, 2025
Chairperson: Ernesto Guccione, USA
Michal Lotem
Head of The Hadassah Cancer Research Institute (HCRI), Hadassah Hebrew University Medical Center, Israel
Nucleic Acid Therapeutic Unlabeled Reporter Assay (NATURA): A novel platform for high-throughput quantification of NATs’ functional delivery and potency
Ernesto Guccione
Principal Investigator, The Guccione Lab, Icahn School of Medicine at Mount Sinai, USA
Modeling and Modulating Antitumor Immunity with RNA nanoparticles in 3D-Bioprinted Tumoroids
Ronit Satchi-Fainaro
Director, Cancer Biology Research Center, and Director, TAU Kahn 3D BioPrinting Initiative, TAU, Israel
DELiveri: Massive throughput screens to identify conjugates that promote cell delivery of nucleic acid therapeutics
Omer Ziv, Executive Director of RNA Biology, Eleven Therapeutics, UK
Improved Delivery of RNAs for Extra-Hepatic Delivery
Ruben Postel
CSO & Scientific Founder, Sapreme Technologies, The Netherlands
Endosomal Escape Technology Enabling ASO Delivery and Therapeutic Applications
François-Thomas Michaud
CEO, Feldan Therapeutics, Canada
Advancing RNA Therapeutics with RNA Engineering and Targeted Lipid Nanoparticles Delivery
Min Wen Ku
Application Scientist, VectorBuilder, UK
Chairperson: Claudio Sette, Italy
Splicing dysregulation: Hallmark and therapeutic opportunity in cancer
Claudio Sette
Principal Investigator, Catholic University of the Sacred Heart, School of Medicine, Italy
Pseudoexon activation as a therapeutic approach
Brage Storstein Andresen
Head of Research, RNA Splicing and Disease Lab, University of Southern Denmark
A Proprietary Circular RNA Platform for the Treatment of Infectious Diseases, Cancers, Autoimmune and Other Diseases
Peter D. Weinstein
Chief Executive Officer/General Counsel, Emervax Inc., USA
FlashRNA®: A Disruptive RNA Delivery Technology for Next-Generation Therapies
Christine Duthoit
CEO – CSO, RNAlead, France
Targeting the splicing factor RBM39 reduces mitotic fidelity and enhances taxane cytotoxicity in triple negative breast cancer cells
Chiara Naro
Department of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Heart, Rome; GSTeP-Organoids Research Core Facility, IRCCS Fondazione Policlinico A. Gemelli, Rome, Italy
HnRNP C binding to inverted Alu elements protects the transcriptome from pre-mRNA circularization
Sabrina Ciccone
Department of Neuroscience, Section of Human Anatomy, Università Cattolica del Sacro Cuore, Italy
RBFOX2 binding to a single pre-mRNA binding site dictates complete exon cassette inclusion
Carlos Nino
IFOM ETS – The AIRC Institute of Molecular Oncology, Milan, Italy
Chairperson: Michal Lotem, Israel
Dual-function oligonucleotide strategies for immunotherapy of acute myeloid leukemia
Marcin Kortylewski
Principal Investigator, The Kortylewski Lab, City of Hope, USA
Therapeutic approaches for HNRNPH2-Related Neurodevelopmental Disorder, an ultra-rare neurogenetic disorder
Christopher Ricupero
Assistant Professor, Columbia University Irving Medical Center, USA
Decoding Cancer Complexity: Machine Learning and Transcriptomic Signatures
Shai Rosenberg
Head of the Computational Medicine Service, Hadassah Hebrew University Medical Center, Israel
Local microRNA therapy rescues cognitive and motor deficits associated with tau pathology
Elena Avale
INGEBI-CONICET, Buenos Aires, Argentina
Complementation of a Human Disease Phenotype By Intercellular mRNA Transfer
Gal Haimovich
Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel
Targeted mRNA-LNP Delivery for Gene-Editing in Murine Lungs and Human Airway Epithelium
Sharad Saxena
ICGEB, Trieste, Italy
Chairperson: Michal Lotem, Israel
Developing RNA based approaches for the treatment of Pompe Disease and neurodegenerative conditions
Emanuele Buratti
Group Leader, Molecular Pathology Lab, ICGEB, Italy
Chemistry Meets Biology: Enabling RNA Therapeutics Through Custom Oligo Synthesis
Talia Waxenbaum, Business & Sales Leader, 1E Pharma Solutions, Israel
Enabling Precision Medicine: From Liquid Biopsy to Antigen Discovery with Next-Gen Technologies
Massimiliano Clamer
Chairman & Founder, Immagina Biotechnology, Italy
Aptamer-Guided Strategies To Enhance Aso Therapeutics
Fernando Pastor
RNA Biology and Therapy; Therapeutic Innovation, Aptamer Unit, Center for Applied Medical Research (CIMA), University of Navarra (UNAV), Pamplona, Spain
Splicing inhibitors as dual-action therapeutics for chemoresistant triple-negative breast cancer
Cinzia Caggiano
Catholic University of the Sacred Heart, Policlinico Universitario Agostino Gemelli, Italy
Shaping the Future of RNA Therapeutics: Innovation, Investment, and Impact
Panelists:
Yael Gruenbaum Cohen, Partner & Head, aMoon Alpha, Israel
Tamar Grossman, CEO, La Jolla Labs, USA
THURSDAY, OCTOBER 30, 2025
Please click here to view the list of posters.
Chairperson: Ernesto Guccione, USA
Targeting noncoding elements to boost haploinsufficient gene expression
Igor Ulitsky
Principal Investigator, Ulitsky Lab, Weizmann Institute of Science, Israel
Small and long non-coding RNA transforming cell fates in the brain
Anna Krichevsky
Professor of Neurology, Brigham and Women’s Hospital and Harvard Medical School, USA
Exploiting the dark genome to target drug-tolerant cells and improve anticancer immune therapies
Eleonora Leucci
Principal Investigator – RNA Cancer Biology Lab, KU Leuven, Belgium
A Claudinlow-specific splicing signature identifies prognostic and therapeutic targets in gastric cancer
Diletta Dolfini
Dipartimento di Bioscienze, Università degli Studi di Milano, Italy
Bispecific siRNA to reduce Cardiometabolic Risk
Michael Khan
Chief Executive Officer, Argonaute RNA, UK
Chairperson: Ernesto Guccione, USA
SRSF1-regulated alternative splicing controls on oncogenic circuit in pancreatic cancer
Adrian R. Krainer
St. Giles Foundation Professor, Cold Spring Harbor Laboratory, New York, USA
Targeted delivery of therapeutic oligonucleotides for the treatment of neuromuscular diseases
Oxana Beskrovnaya
Chief Innovation Officer, Dyne Therapeutics, USA
Targeting miR-22 with an Antisense Oligonucleotide: a new RNA-based paradigm for treating obesity
Riccardo Panella, Chief Scientific Officer, Resalis Therapeutics, Italy
A novel IV-delivered gene-silencing therapeutic with a potential to halt Huntington’s Disease (HD)
Yacoub Habib
Ophidion, Inc., USA
Oligonucleotide-based nanotherapies for the treatment of skeletal muscle diseases
Daniela Palacios
National Research Council, Rome, Italy
Chairperson: Rotem Karni, Israel / USA
Rewriting the Message: RNA Splice Disruption Unmasks New Cancer Immunotherapy Targets
Michal Lotem
Head of The Hadassah Cancer Research Institute (HCRI), Hadassah Hebrew University Medical Center, Israel
Aberrantly spliced cancer proteoforms: If you can’t beat them, eat them!
Andrei Thomas-Tikhonenko
Director of Experimental Pathology, Children’s Hospital of Philadelphia, USA
Enhancing Anti-Tumor Immune Response By Modulating Splicing To Generate Neoantigens
Anurag V. Prabhu
Department of Biochemistry and Molecular Biology, IMRIC, Hebrew University of Jerusalem, Israel
Chairperson: Rotem Karni, Israel / USA
Targeting RNA processing to induce neoantigen in cancer cells
Rotem Karni
Principal Investigator, Hebrew University-Hadassah Medical School, Israel and University of Pennsylvania, USA
A novel regulatory circuit required for tumor angiogenesis and cancer growth
Claudia Ghigna
Scientist, Institute of Molecular Genetics, Italy
Novel Targeted Thiopurine-Based Oligonucleotide Therapies via Direct Telomere Disruption and Immune Activation
Zoya Gluzman-Poltorak
CEO & Co-Founder, Forta Bio, Inc., CA, USA
Exploiting RNA Surveillance Mechanisms as Therapeutic Vulnerabilities in MYC-Driven Lymphomas
Maria Musarra Pizzo
European Institute of Oncology (IEO), Milan, Italy
Exploiting Lipid Nanoparticles to Target HLX in Childhood Cancer Medulloblastoma
Ranjan Perera
Cancer and Blood Disorders Institute, Center of RNA Biology and Therapy, Johns Hopkins All Children’s Hospital, St. Petersburg; Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
Chairperson: Claudio Sette, Italy
Exploiting RNA translation control to fight cancer resistance
Caroline Robert
Head of Dermatology, Gustave Roussy Institute, France
Ultra-conserved poison exons in SR protein splicing regulator genes: Do these operate as tumour suppressors or protect the functions of specific cell types?
David Elliott
Principal Investigator, Newcastle University, UK
Chairperson: Claudio Sette, Italy
Targeting m6A-RNA Biology in FTO-Dependent Cancers
Amir Mor
CSO, RNAble, Israel
Evaluating Lipid Nanoparticle-Encapsulated Decoy Oligonucleotides for the Treatment of Myeloid Malignancies
Carla Azar
Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel-Canada, Hebrew-University-Hadassah Medical School, Jerusalem, Israel
Decoding Delivery: Machine Learning-Driven Optimization of targeting via Barcoded Nanoparticles
Annie Sabbah
CTO and Co-founder, Barcode Nanotech, Israel
Chairperson: Rotem Karni, Israel / USA
Harnessing RNA-Driven Intelligence to Revolutionize Personalized Cancer Therapy
Aron Popovtzer
Director of the Sharett Institute of Oncology, Hadassah Medical Center, Israel
miRNA-based logic circuits encoded on self-amplifying RNA for highly specific cancer cell classification
Ron Weiss
Principal Investigator, The Weiss Lab, Massachusetts Institute of Technology, USA
Chairperson: Rotem Karni, Israel / USA
AI-Driven Design: Unlocking Novel Mechanisms in RNA Therapeutics
Tamar Grossman
CEO, La Jolla Labs, USA
Deep Generative Models for RNA Processing Prediction and Design
Yoseph Barash
Professor of Genetics, Perelman School of Medicine, University of Pennsylvania, USA
Please click here to view the list of posters.
